Compare ARW & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARW | PTCT |
|---|---|---|
| Founded | 1935 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.7B |
| IPO Year | 1994 | 2006 |
| Metric | ARW | PTCT |
|---|---|---|
| Price | $175.97 | $72.40 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 17 |
| Target Price | ★ $136.00 | $80.65 |
| AVG Volume (30 Days) | 470.9K | ★ 750.6K |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 49.93 | ★ 264.48 |
| EPS | ★ 10.93 | 7.78 |
| Revenue | ★ $30,852,935,000.00 | $264,734,000.00 |
| Revenue This Year | $13.55 | N/A |
| Revenue Next Year | $4.58 | $19.02 |
| P/E Ratio | $16.07 | ★ $9.29 |
| Revenue Growth | 10.49 | ★ 36.19 |
| 52 Week Low | $101.79 | $35.95 |
| 52 Week High | $179.28 | $87.50 |
| Indicator | ARW | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 73.88 | 58.99 |
| Support Level | $109.60 | $69.81 |
| Resistance Level | N/A | $79.59 |
| Average True Range (ATR) | 5.19 | 2.25 |
| MACD | 2.65 | 0.47 |
| Stochastic Oscillator | 91.39 | 81.77 |
Arrow Electronics Inc. is a provider of products, services, and solutions to industrial and commercial users of electronic components and enterprise computing solutions. It has one of the world's broadest portfolios of product offerings available from electronic components and enterprise computing solutions suppliers, coupled with a range of services, solutions, and software, the company helps industrial and commercial customers introduce products, reduce their time to market, and enhance their overall competitiveness. The company has two business segments, the global components business and the global enterprise computing solutions.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.